Photograph: Arnd Wiegmann/Reuters

Roche is buying US-based gene therapy specialist Spark Therapeutics for $4.3 billion (€3.78 billion) after developments in this area convinced the Swi(...)

  Roche shares surged after two experimental medicines succeeded in much-anticipated patient trials. Photograph: Steffen Schmidt / EPA

Roche shares surged after two experimental medicines for cancer and haemophilia succeeded in much-anticipated patient trials, boding well for the Swis(...)

Emma Walmsley will be paid an annual base salary of about £1 million

Emma Walmsley, poised to take over as the first female chief executive of GlaxoSmithKline, will earn about a quarter less than her predecessor Andrew (...)

New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing com(...)

A Roche logo sits on a sign outside Roche Holding’s headquarters in Basel, Switzerland.  Photograph: Philipp Schmidli/Bloomberg

Switzerland’s Roche expects no copycat competition to its biotech cancer drugs for another two years, giving it space to grow a successful portfolio o(...)

Roche shares fall as much as 4.1 per cent. Photograph: Reuters

Roche Holding AG, the world’s largest seller of cancer drugs, said the Swiss franc’s surge may strip 9 percentage points from growth in operating prof(...)

Roche, the world’s largest maker of cancer drugs, will pay $74 a share for InterMune, an unprofitable biotechnology company that’s awaiting US approval of its biggest drug.Photograph: STEFFEN SCHMIDT/EPA

Roche Holding, the world’s largest maker of cancer drugs, is strengthening its portfolio of medicines for respiratory ailments with an agreement to bu(...)

 Christoph Franz (left), designated chairman of the board, speaks to Franz B Humer, outgoing chairman of the board of Roche, during the general assembly of Swiss pharmaceutical company Roche Holding AG in Basel, Switzerland, yesterday. Photograph: EPA/Patrick Straub

Roche’s new chairman has signalled his intention to follow his predecessor’s tight-fisted approach toward acquisitions even now that the drugma(...)

Swiss group Roche yesterday posted an 8 per cent rise in third-quarter sales in local currencies, helped by strong uptake of two new breast cancer drugs. Photograph: AP Photo

Strong demand for Roche’s speciality cancer medicines, many of which are bought privately in emerging markets, has helped it defy an expected slowdown(...)